Fang-Fei Wei

Sep 5, 2024 | nature.com | Fang-Fei Wei |Pierpaolo Pellicori |Joao Ferreira |Arantxa González |De-Wei An |Chen Liu | +10 more

AbstractNone of the spironolactone trials in heart failure (HF) assessed the blood pressure (BP) responses to exercise, while conflicting results were reported for exercise capacity. In the HOMAGE trial, 527 patients at increased HF risk were randomized to usual treatment with or without spironolactone (25–50 mg/day). The current substudy included 113 controls and 114 patients assigned spironolactone, who all completed the incremental shuttle walk test at baseline and months 1 and 9.